Recent Breakthroughs and Emerging Trends in Gullain Barre Syndrome

Guillain-Barré Syndrome (GBS) is an acute autoimmune polyneuropathy causing progressive weakness, loss of reflexes, and sensory or autonomic dysfunction. It often follows Campylobacter jejuni infection due to molecular mimicry between microbial and nerve antigens. GBS affects 1–2 per 100,000 people annually, mainly males and older adults. Subtypes include AIDP, AMAN, AMSAN, and Miller Fisher syndrome. Diagnosis relies on clinical signs, CSF analysis, and nerve conduction studies. Early treatment with IVIG or plasma exchange improves outcomes, though some patients face lasting disability or death. Supportive care, physiotherapy, and new immunotherapies enhance recovery, while infection prevention helps reduce risk.

Polyneuropathy, Acute flaccid paralysis, Autoimmune response

1. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123–133. [Google Scholar] [Crossref]

2. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–727. [Google Scholar] [Crossref]

3. Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–482. [Google Scholar] [Crossref]

4. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(S1): S21–24. [Google Scholar] [Crossref]

5. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012;366(24):2294–2304. [Google Scholar] [Crossref]

6. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063. [Google Scholar] [Crossref]

7. Hughes RAC, Wijdicks EFM, Benson E, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome. Neurology. 2003;61(6):736–740. [Google Scholar] [Crossref]

8. Hadden RDM, Cornblath DR, Hughes RAC, et al. Electrodiagnostic criteria for Guillain-Barré syndrome: a consensus statement. Ann Neurol. 1998;44(5):780–788. [Google Scholar] [Crossref]

9. Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol. 2013;12(12):1180–1188. [Google Scholar] [Crossref]

10. Jacobs BC, Rothbarth PH, van der Meché FGA, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110–1115. [Google Scholar] [Crossref]

11. Wakerley BR, Uncini A, Yuki N. Guillain-Barré and Miller Fisher syndromes—new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–544. [Google Scholar] [Crossref]

12. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–683. [Google Scholar] [Crossref]

13. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214–1228. [Google Scholar] [Crossref]

14. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33(4):333–342. [Google Scholar] [Crossref]

15. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal–cervical–brachial variant of Guillain–Barré syndrome. Arch Neurol. 2007;64(10):1519–1523. [Google Scholar] [Crossref]

16. Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31(2):491–510. [Google Scholar] [Crossref]

17. Hughes RAC, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130(9):2245–2257. [Google Scholar] [Crossref]

18. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349(9047):225–230. [Google Scholar] [Crossref]

19. Lawn ND, Wijdicks EFM. Fatal Guillain-Barré syndrome. Neurology. 1999;52(3):635–638. [Google Scholar] [Crossref]

20. Dhar R, Stitt L, Hahn AF. The morbidity and outcome of Guillain-Barré syndrome associated with mechanical ventilation. Can J Neurol Sci. 2008;35(4):443–446 [Google Scholar] [Crossref]

21. Sri Ramachandra M, Kavya G, Vijay Teja V, Irshad S. A review on Guillain–Barre syndrome. Int J Adv Pharm Sci (IAJPS). 2025;12(8):7-13. [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities